SVNT Financial Facts

Research and development: 4.15M
Loss before income taxes: -20.43M
See Full Income Statement

Accrued interest on convertible notes: 2.98M
Total liabilities and stockholders' equity: 56.14M
See Full Balance Sheet

Savient Pharmaceuticals, Inc. (SVNT) Earnings

  |   Expand Research on SVNT
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate -7.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -4.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/4/11 Q211 -$0.43-$0.30 -$0.13$2M$2.77M N/A Details
11/8/12 Q312 -$0.56-$0.48 -$0.08$4.9M$5.85M N/A Details
2/27/12 Q411 -$0.44-$0.38 -$0.06$3.71M$3.51M N/A Details
8/7/13 Q213 -$0.35-$0.31 -$0.04$6.7M$5.84M N/A Details
5/15/13 Q113 -$0.34-$0.31 -$0.03$4.7M$5.65M N/A Details
5/9/12 Q112 -$0.49-$0.46 -$0.03$3.5M$4.59M N/A Details
11/3/11 Q311 -$0.39-$0.40 +$0.01$2.58M$3.17M N/A Details
3/19/13 Q412 -$0.39-$0.44 +$0.05$4.95M$6.18M N/A Details